| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 95 | 2024 | 1721 | 13.550 |
Why?
|
| Cystectomy | 16 | 2023 | 102 | 5.170 |
Why?
|
| Patient Readmission | 18 | 2023 | 329 | 4.660 |
Why?
|
| Urinary Bladder Neoplasms | 20 | 2023 | 383 | 4.430 |
Why?
|
| Delivery of Health Care | 21 | 2023 | 426 | 3.680 |
Why?
|
| Urology | 13 | 2023 | 110 | 3.460 |
Why?
|
| Prostate-Specific Antigen | 19 | 2023 | 353 | 3.330 |
Why?
|
| Prostatectomy | 20 | 2023 | 471 | 3.200 |
Why?
|
| Androgen Antagonists | 11 | 2023 | 144 | 3.140 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 6 | 2023 | 111 | 2.600 |
Why?
|
| Male | 141 | 2024 | 40965 | 2.390 |
Why?
|
| Humans | 175 | 2024 | 86643 | 1.960 |
Why?
|
| Aged | 90 | 2023 | 18415 | 1.960 |
Why?
|
| United States | 65 | 2023 | 6672 | 1.890 |
Why?
|
| Quality of Health Care | 13 | 2019 | 380 | 1.850 |
Why?
|
| Survivors | 9 | 2016 | 226 | 1.740 |
Why?
|
| Postoperative Complications | 14 | 2020 | 2207 | 1.700 |
Why?
|
| Cancer Survivors | 5 | 2022 | 85 | 1.630 |
Why?
|
| Prostatic Hyperplasia | 3 | 2019 | 88 | 1.620 |
Why?
|
| Veterans | 4 | 2021 | 72 | 1.610 |
Why?
|
| Prostate | 9 | 2023 | 378 | 1.580 |
Why?
|
| Medicare | 27 | 2023 | 410 | 1.580 |
Why?
|
| Veterans Health | 7 | 2020 | 15 | 1.580 |
Why?
|
| Survivorship | 5 | 2021 | 18 | 1.560 |
Why?
|
| Quality of Life | 18 | 2023 | 1585 | 1.490 |
Why?
|
| Telemedicine | 6 | 2020 | 169 | 1.490 |
Why?
|
| Urologic Neoplasms | 4 | 2020 | 77 | 1.480 |
Why?
|
| United States Department of Veterans Affairs | 11 | 2021 | 26 | 1.450 |
Why?
|
| Self-Management | 3 | 2019 | 29 | 1.430 |
Why?
|
| Practice Patterns, Physicians' | 15 | 2021 | 582 | 1.400 |
Why?
|
| Patient Discharge | 8 | 2023 | 300 | 1.390 |
Why?
|
| Primary Health Care | 5 | 2020 | 339 | 1.340 |
Why?
|
| Research Design | 7 | 2021 | 594 | 1.300 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1169 | 1.270 |
Why?
|
| Aged, 80 and over | 35 | 2020 | 6509 | 1.070 |
Why?
|
| Sexual Partners | 7 | 2022 | 93 | 1.070 |
Why?
|
| Physicians, Primary Care | 3 | 2024 | 104 | 1.060 |
Why?
|
| Neoplasms | 7 | 2023 | 2898 | 1.040 |
Why?
|
| Osteoporosis | 2 | 2017 | 121 | 1.020 |
Why?
|
| Robotics | 4 | 2012 | 267 | 0.990 |
Why?
|
| Surgical Procedures, Operative | 4 | 2020 | 182 | 0.980 |
Why?
|
| Treatment Outcome | 24 | 2023 | 7993 | 0.980 |
Why?
|
| Medical Oncology | 3 | 2017 | 359 | 0.960 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 203 | 0.950 |
Why?
|
| Retrospective Studies | 42 | 2023 | 8489 | 0.940 |
Why?
|
| Androstenes | 5 | 2023 | 43 | 0.920 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 150 | 0.900 |
Why?
|
| Urinary Catheterization | 2 | 2019 | 35 | 0.880 |
Why?
|
| Phenylthiohydantoin | 4 | 2021 | 41 | 0.870 |
Why?
|
| Medicare Part D | 3 | 2021 | 10 | 0.870 |
Why?
|
| Bibliometrics | 2 | 2019 | 37 | 0.860 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.850 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2019 | 111 | 0.840 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 351 | 0.840 |
Why?
|
| Middle Aged | 42 | 2023 | 25028 | 0.830 |
Why?
|
| Aftercare | 4 | 2023 | 85 | 0.810 |
Why?
|
| Names | 1 | 2021 | 10 | 0.800 |
Why?
|
| Life Expectancy | 6 | 2021 | 86 | 0.790 |
Why?
|
| Urologists | 6 | 2024 | 24 | 0.770 |
Why?
|
| Drug Prescriptions | 3 | 2021 | 141 | 0.760 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 1939 | 0.750 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 322 | 0.740 |
Why?
|
| Reimbursement, Incentive | 1 | 2020 | 37 | 0.730 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2019 | 9 | 0.730 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2017 | 173 | 0.720 |
Why?
|
| Physicians | 3 | 2023 | 673 | 0.720 |
Why?
|
| Sexual Dysfunction, Physiological | 4 | 2022 | 67 | 0.720 |
Why?
|
| Urinary Diversion | 2 | 2017 | 42 | 0.710 |
Why?
|
| Information Dissemination | 2 | 2017 | 103 | 0.710 |
Why?
|
| Health Expenditures | 3 | 2020 | 86 | 0.700 |
Why?
|
| Electronic Health Records | 3 | 2021 | 319 | 0.700 |
Why?
|
| Orchiectomy | 2 | 2018 | 68 | 0.690 |
Why?
|
| SEER Program | 16 | 2022 | 190 | 0.690 |
Why?
|
| Castration | 1 | 2018 | 41 | 0.680 |
Why?
|
| Accountable Care Organizations | 5 | 2019 | 13 | 0.680 |
Why?
|
| Logistic Models | 10 | 2021 | 1186 | 0.670 |
Why?
|
| Publishing | 1 | 2019 | 90 | 0.670 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2019 | 102 | 0.670 |
Why?
|
| Models, Theoretical | 2 | 2019 | 482 | 0.660 |
Why?
|
| Length of Stay | 6 | 2020 | 702 | 0.640 |
Why?
|
| Spouses | 2 | 2017 | 33 | 0.640 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 45 | 0.630 |
Why?
|
| Watchful Waiting | 5 | 2024 | 60 | 0.630 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 56 | 0.620 |
Why?
|
| Urinary Bladder | 2 | 2017 | 246 | 0.620 |
Why?
|
| Machine Learning | 1 | 2020 | 232 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1036 | 0.610 |
Why?
|
| Surgeons | 2 | 2020 | 238 | 0.610 |
Why?
|
| Insurance Coverage | 2 | 2020 | 117 | 0.610 |
Why?
|
| Erectile Dysfunction | 6 | 2017 | 74 | 0.590 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2019 | 57 | 0.590 |
Why?
|
| Interviews as Topic | 3 | 2019 | 319 | 0.580 |
Why?
|
| Time Factors | 13 | 2019 | 5210 | 0.580 |
Why?
|
| Odds Ratio | 8 | 2019 | 678 | 0.580 |
Why?
|
| Health Education | 1 | 2017 | 101 | 0.580 |
Why?
|
| Female | 40 | 2021 | 44532 | 0.570 |
Why?
|
| Kidney Neoplasms | 4 | 2010 | 621 | 0.570 |
Why?
|
| Survival Rate | 11 | 2020 | 1863 | 0.570 |
Why?
|
| Replantation | 1 | 2016 | 36 | 0.560 |
Why?
|
| Fractures, Bone | 1 | 2017 | 131 | 0.560 |
Why?
|
| Hospital Costs | 1 | 2017 | 105 | 0.560 |
Why?
|
| Ureteral Obstruction | 1 | 2016 | 67 | 0.550 |
Why?
|
| Self Care | 1 | 2017 | 164 | 0.540 |
Why?
|
| Consumer Health Information | 1 | 2015 | 13 | 0.540 |
Why?
|
| Nitriles | 6 | 2023 | 149 | 0.530 |
Why?
|
| Ureter | 1 | 2016 | 92 | 0.530 |
Why?
|
| Unnecessary Procedures | 6 | 2020 | 51 | 0.510 |
Why?
|
| Rural Population | 3 | 2015 | 136 | 0.500 |
Why?
|
| Cohort Studies | 15 | 2021 | 2767 | 0.500 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 45 | 0.490 |
Why?
|
| Cost of Illness | 2 | 2017 | 150 | 0.490 |
Why?
|
| Health Care Costs | 7 | 2019 | 238 | 0.490 |
Why?
|
| Exercise Therapy | 1 | 2014 | 80 | 0.490 |
Why?
|
| Biomedical Research | 2 | 2018 | 376 | 0.480 |
Why?
|
| Androgens | 3 | 2023 | 167 | 0.480 |
Why?
|
| Health Services Accessibility | 5 | 2020 | 394 | 0.460 |
Why?
|
| Peripheral Nerves | 1 | 2013 | 36 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1313 | 0.440 |
Why?
|
| Physician-Patient Relations | 2 | 2015 | 610 | 0.440 |
Why?
|
| Quality Improvement | 5 | 2022 | 428 | 0.430 |
Why?
|
| Robotic Surgical Procedures | 2 | 2017 | 267 | 0.430 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 169 | 0.430 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 999 | 0.430 |
Why?
|
| Automation | 1 | 2012 | 106 | 0.430 |
Why?
|
| Prognosis | 11 | 2022 | 3679 | 0.420 |
Why?
|
| Communication | 1 | 2015 | 441 | 0.420 |
Why?
|
| Surveys and Questionnaires | 5 | 2021 | 2501 | 0.410 |
Why?
|
| Taxoids | 2 | 2023 | 129 | 0.410 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1464 | 0.400 |
Why?
|
| Cost Savings | 4 | 2019 | 66 | 0.400 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 53 | 0.400 |
Why?
|
| Urogenital Neoplasms | 2 | 2020 | 23 | 0.380 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 549 | 0.370 |
Why?
|
| Lymph Node Excision | 2 | 2010 | 217 | 0.370 |
Why?
|
| Guideline Adherence | 5 | 2021 | 223 | 0.370 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1169 | 0.360 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2360 | 0.350 |
Why?
|
| BCG Vaccine | 1 | 2009 | 31 | 0.350 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2010 | 99 | 0.350 |
Why?
|
| Health Services Needs and Demand | 3 | 2020 | 102 | 0.340 |
Why?
|
| Urologic Surgical Procedures | 1 | 2010 | 146 | 0.340 |
Why?
|
| Drug Industry | 3 | 2023 | 54 | 0.330 |
Why?
|
| Urinary Incontinence | 3 | 2022 | 206 | 0.330 |
Why?
|
| Retroperitoneal Space | 1 | 2008 | 38 | 0.330 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 1204 | 0.330 |
Why?
|
| Health Resources | 2 | 2020 | 76 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2601 | 0.320 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 257 | 0.320 |
Why?
|
| Risk Factors | 8 | 2019 | 5417 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 865 | 0.310 |
Why?
|
| Health Care Reform | 3 | 2016 | 90 | 0.310 |
Why?
|
| Clinical Protocols | 2 | 2018 | 156 | 0.310 |
Why?
|
| Testicular Neoplasms | 1 | 2008 | 105 | 0.300 |
Why?
|
| Sexual Behavior | 7 | 2022 | 302 | 0.300 |
Why?
|
| Health Services | 2 | 2017 | 55 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 318 | 0.300 |
Why?
|
| Perioperative Care | 2 | 2019 | 161 | 0.300 |
Why?
|
| Penile Erection | 2 | 2018 | 22 | 0.290 |
Why?
|
| Adult | 14 | 2023 | 25648 | 0.290 |
Why?
|
| Reimbursement Mechanisms | 2 | 2019 | 41 | 0.290 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 357 | 0.290 |
Why?
|
| Patient Preference | 2 | 2018 | 105 | 0.280 |
Why?
|
| Age Factors | 3 | 2019 | 1851 | 0.280 |
Why?
|
| Kallikreins | 2 | 2016 | 47 | 0.280 |
Why?
|
| Benzamides | 4 | 2021 | 229 | 0.270 |
Why?
|
| Registries | 3 | 2021 | 702 | 0.270 |
Why?
|
| Diffusion of Innovation | 4 | 2014 | 71 | 0.270 |
Why?
|
| Prospective Studies | 7 | 2023 | 4213 | 0.270 |
Why?
|
| Remote Consultation | 2 | 2015 | 16 | 0.270 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 394 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 0.260 |
Why?
|
| Urologic Diseases | 2 | 2015 | 45 | 0.260 |
Why?
|
| Biopsy | 4 | 2022 | 1163 | 0.250 |
Why?
|
| Body Mass Index | 1 | 2007 | 770 | 0.240 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 166 | 0.240 |
Why?
|
| Incidence | 3 | 2021 | 1577 | 0.240 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 1621 | 0.240 |
Why?
|
| Pyrimidinones | 1 | 2023 | 36 | 0.240 |
Why?
|
| Ketoconazole | 1 | 2023 | 25 | 0.230 |
Why?
|
| Certificate of Need | 2 | 2012 | 3 | 0.220 |
Why?
|
| Risk Adjustment | 2 | 2019 | 39 | 0.220 |
Why?
|
| Sexual Health | 1 | 2022 | 14 | 0.220 |
Why?
|
| Mass Screening | 3 | 2019 | 618 | 0.210 |
Why?
|
| Psychometrics | 2 | 2021 | 327 | 0.210 |
Why?
|
| Health Services Misuse | 2 | 2012 | 19 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2023 | 256 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 552 | 0.210 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2023 | 120 | 0.210 |
Why?
|
| Patient Selection | 3 | 2020 | 685 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1673 | 0.200 |
Why?
|
| Databases, Factual | 4 | 2020 | 814 | 0.200 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 860 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 468 | 0.200 |
Why?
|
| Hospitalization | 2 | 2017 | 849 | 0.200 |
Why?
|
| Laparoscopy | 1 | 2008 | 754 | 0.200 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 379 | 0.200 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 20 | 0.200 |
Why?
|
| Brachytherapy | 2 | 2015 | 119 | 0.200 |
Why?
|
| Data Accuracy | 2 | 2018 | 31 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 859 | 0.190 |
Why?
|
| Oncology Service, Hospital | 1 | 2020 | 6 | 0.190 |
Why?
|
| Geography | 1 | 2021 | 223 | 0.190 |
Why?
|
| Obesity | 1 | 2007 | 963 | 0.190 |
Why?
|
| Urination Disorders | 2 | 2011 | 50 | 0.190 |
Why?
|
| Pandemics | 3 | 2023 | 740 | 0.190 |
Why?
|
| Nephrectomy | 2 | 2016 | 294 | 0.190 |
Why?
|
| Patient Care Management | 2 | 2017 | 31 | 0.190 |
Why?
|
| Physical Fitness | 1 | 2020 | 51 | 0.180 |
Why?
|
| Urinary Catheters | 1 | 2019 | 6 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2019 | 18 | 0.180 |
Why?
|
| Florida | 1 | 2019 | 55 | 0.180 |
Why?
|
| Conservative Treatment | 1 | 2019 | 20 | 0.180 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 21 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 297 | 0.180 |
Why?
|
| Economics, Hospital | 1 | 2019 | 11 | 0.180 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2705 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 2438 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 508 | 0.170 |
Why?
|
| Medication Adherence | 1 | 2020 | 129 | 0.170 |
Why?
|
| Postoperative Period | 1 | 2020 | 303 | 0.170 |
Why?
|
| Mastectomy | 1 | 2021 | 243 | 0.170 |
Why?
|
| Margins of Excision | 1 | 2018 | 39 | 0.170 |
Why?
|
| Urethral Stricture | 1 | 2018 | 13 | 0.170 |
Why?
|
| Subacute Care | 1 | 2018 | 13 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 220 | 0.170 |
Why?
|
| Insurance Benefits | 1 | 2018 | 8 | 0.160 |
Why?
|
| Self-Help Devices | 1 | 2018 | 6 | 0.160 |
Why?
|
| Health Services Research | 2 | 2016 | 136 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1686 | 0.160 |
Why?
|
| Parents | 1 | 2021 | 272 | 0.160 |
Why?
|
| Internet | 2 | 2017 | 312 | 0.160 |
Why?
|
| Hand Disinfection | 1 | 2018 | 17 | 0.160 |
Why?
|
| Device Removal | 1 | 2019 | 161 | 0.160 |
Why?
|
| Men's Health | 1 | 2017 | 6 | 0.160 |
Why?
|
| Teaching Materials | 1 | 2017 | 12 | 0.150 |
Why?
|
| Practice Management, Medical | 1 | 2017 | 24 | 0.150 |
Why?
|
| Urethra | 1 | 2018 | 113 | 0.150 |
Why?
|
| Public Sector | 1 | 2017 | 12 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2018 | 233 | 0.150 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2017 | 32 | 0.150 |
Why?
|
| Academies and Institutes | 1 | 2017 | 31 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 38 | 0.150 |
Why?
|
| Recovery of Function | 3 | 2015 | 272 | 0.150 |
Why?
|
| Exercise | 2 | 2023 | 315 | 0.150 |
Why?
|
| Nephrotomy | 1 | 2016 | 1 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2017 | 91 | 0.150 |
Why?
|
| Hospital Communication Systems | 1 | 2016 | 4 | 0.150 |
Why?
|
| Attitude to Health | 3 | 2014 | 220 | 0.150 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 128 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2020 | 572 | 0.140 |
Why?
|
| Failure to Thrive | 1 | 2016 | 17 | 0.140 |
Why?
|
| Confidence Intervals | 2 | 2016 | 229 | 0.140 |
Why?
|
| Bone Density | 1 | 2017 | 209 | 0.140 |
Why?
|
| Information Seeking Behavior | 1 | 2016 | 12 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2016 | 81 | 0.140 |
Why?
|
| Japan | 1 | 2016 | 307 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2018 | 839 | 0.140 |
Why?
|
| General Surgery | 1 | 2018 | 229 | 0.140 |
Why?
|
| Language | 1 | 2017 | 151 | 0.140 |
Why?
|
| Fever | 1 | 2016 | 125 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2020 | 751 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 130 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2010 | 426 | 0.130 |
Why?
|
| Creatinine | 1 | 2016 | 338 | 0.130 |
Why?
|
| Anastomosis, Surgical | 1 | 2016 | 267 | 0.130 |
Why?
|
| Denosumab | 1 | 2014 | 2 | 0.130 |
Why?
|
| Reproductive Health | 1 | 2015 | 32 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1805 | 0.130 |
Why?
|
| Coitus | 1 | 2014 | 20 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 384 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2014 | 36 | 0.130 |
Why?
|
| American Cancer Society | 1 | 2014 | 13 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2017 | 352 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2017 | 313 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 103 | 0.120 |
Why?
|
| Environment | 1 | 2015 | 219 | 0.120 |
Why?
|
| Stents | 1 | 2016 | 377 | 0.120 |
Why?
|
| Technology Transfer | 1 | 2013 | 3 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 413 | 0.120 |
Why?
|
| Administration, Intravesical | 2 | 2011 | 33 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 289 | 0.110 |
Why?
|
| Adaptation, Psychological | 3 | 2022 | 157 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1056 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3640 | 0.110 |
Why?
|
| Health Promotion | 1 | 2014 | 160 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 144 | 0.110 |
Why?
|
| Vitamin D | 1 | 2014 | 261 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 53 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2021 | 1538 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2015 | 272 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 83 | 0.100 |
Why?
|
| Diet | 1 | 2015 | 443 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 162 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 429 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 509 | 0.100 |
Why?
|
| Physician Assistants | 1 | 2011 | 19 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2020 | 1004 | 0.100 |
Why?
|
| Nurse Practitioners | 1 | 2011 | 32 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2016 | 2261 | 0.100 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 29 | 0.100 |
Why?
|
| Comorbidity | 3 | 2019 | 943 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 455 | 0.090 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2009 | 28 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2010 | 112 | 0.090 |
Why?
|
| Calcium | 1 | 2014 | 1156 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 364 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 930 | 0.090 |
Why?
|
| Valsalva Maneuver | 1 | 2008 | 6 | 0.080 |
Why?
|
| Insurance Claim Review | 2 | 2019 | 41 | 0.080 |
Why?
|
| Dissection | 1 | 2008 | 42 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 5976 | 0.080 |
Why?
|
| Cough | 1 | 2008 | 54 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 454 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 486 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2008 | 109 | 0.080 |
Why?
|
| Colectomy | 2 | 2019 | 167 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2019 | 112 | 0.080 |
Why?
|
| Suburethral Slings | 1 | 2008 | 73 | 0.080 |
Why?
|
| Adolescent | 2 | 2017 | 8981 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2903 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 371 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 285 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 125 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 894 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 469 | 0.070 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2008 | 192 | 0.070 |
Why?
|
| Risk | 3 | 2013 | 674 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 378 | 0.070 |
Why?
|
| Family Characteristics | 2 | 2014 | 48 | 0.060 |
Why?
|
| Industry | 1 | 2023 | 16 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2023 | 58 | 0.060 |
Why?
|
| Hematuria | 1 | 2023 | 49 | 0.060 |
Why?
|
| Medicaid | 2 | 2019 | 217 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 567 | 0.060 |
Why?
|
| State Medicine | 1 | 2022 | 12 | 0.050 |
Why?
|
| England | 1 | 2022 | 41 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 309 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 62 | 0.050 |
Why?
|
| Group Practice | 1 | 2021 | 7 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2262 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 164 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 238 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 41 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2023 | 280 | 0.050 |
Why?
|
| Data Collection | 1 | 2022 | 372 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 51 | 0.050 |
Why?
|
| Income | 1 | 2020 | 75 | 0.050 |
Why?
|
| Accreditation | 1 | 2020 | 60 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 294 | 0.050 |
Why?
|
| Workflow | 1 | 2020 | 77 | 0.050 |
Why?
|
| Drug Costs | 1 | 2020 | 62 | 0.050 |
Why?
|
| Perception | 1 | 2020 | 168 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 202 | 0.040 |
Why?
|
| Marital Status | 1 | 2019 | 40 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 162 | 0.040 |
Why?
|
| Bias | 1 | 2019 | 127 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 484 | 0.040 |
Why?
|
| Travel | 1 | 2019 | 68 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 684 | 0.040 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2018 | 11 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 41 | 0.040 |
Why?
|
| Michigan | 1 | 2018 | 52 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 278 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 277 | 0.040 |
Why?
|
| Holistic Health | 1 | 2017 | 8 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 235 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1801 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 162 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 2017 | 39 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 327 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 612 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2020 | 574 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 369 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 297 | 0.040 |
Why?
|
| Medical Overuse | 1 | 2016 | 36 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2016 | 53 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2018 | 196 | 0.030 |
Why?
|
| Los Angeles | 1 | 2015 | 28 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 642 | 0.030 |
Why?
|
| Orgasm | 1 | 2014 | 9 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 193 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 751 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 79 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 213 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 189 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 288 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 62 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2012 | 42 | 0.030 |
Why?
|
| State Government | 1 | 2012 | 20 | 0.030 |
Why?
|
| Child | 1 | 2023 | 6927 | 0.030 |
Why?
|
| Mortality | 1 | 2013 | 149 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2011 | 35 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 1531 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2010 | 66 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2011 | 170 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 204 | 0.020 |
Why?
|
| Urodynamics | 1 | 2008 | 122 | 0.020 |
Why?
|